A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

There is positive vaccine news on the Covid-19 variant front, more emotional testimony from the Derek Chauvin trial and it's possibly the best day of the year for baseball fans. Here's what we're ...

It is true that Pfizer had scheduled the first analysis of its data after 32 of its 30,000 trial participants reported cases of COVID-19 — and thought it'd be ready before Election Day.

Pfizer's early data shows COVID-19 vaccine is more than 90% effective 03:51. London — U.S. drugmaker Pfizer said Monday that human trials suggest its coronavirus vaccine is 90% effective at ...

But experts told USA TODAY the claim is based off a misinterpretation of data from a post-surveillance data report published in 2021, in which Pfizer tracked cases of adverse events and fatalities ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Pfizer said Wednesday that a final assessment of trial data on the COVID-19 vaccine it developed in conjunction with German company BioNTech showed it was 95% effective, and that it would apply ...

When the FDA released a 53-page briefing document on Pfizer’s COVID-19 mRNA vaccine candidate yesterday, most readers zeroed in on the shot’s high efficacy in a wide range of demographic groups.

In a 17-4 vote, an expert committee concluded that the scientific evidence supports the authorization of the COVID-19 vaccine from Pfizer and BioNTech for emergency use during the pandemic.

Pfizer and BioNTech have submitted their application to the US Food and Drug Administration for emergency use authorization of their bivalent Covid-19 vaccine for use in people age 12 and older ...

On Monday, pharmaceutical giant Pfizer released more data on its anti-COVID-19 drug, named Paxlovid. The company had released its initial data on the drug in early November, and it looked ...

Pfizer Inc and BioNTech's vaccine was 73.2% effective in preventing COVID-19 among children aged 6 months through 4 years, new data from the companies showed on Tuesday, two months after the U.S ...